Table 2.

The constitution of clinicopathologic features in different CONUT and SIS groups.

Clinicopathologic features	N	CONUT		X2	P	SIS		X2	P
		≤3	>3			≤1	>1
Gender
Male	32	18	14	1.600	0.206	22	10	1.600	0.206
Female	16	12	4			8	8
Age (year)
≤65	24	16	8	0.356	0.551	14	10	0.356	0.551
>65	24	14	10			16	8
ECOG
2	23	16	7	0.941	0.332	15	8	0.139	0.709
0-1	25	14	11			15	10
First line treatment modality
Surgery	22	15	7	0.559	0.454	17	5	3.782	0.052
None-surgery	26	15	11			13	13
Recurrence type
Local regional	35	21	14	0.345	0.557	20	15	1.582	0.208
others	13	9	4			10	3
Interval after treatment failure
≤12 month	15	9	6	0.058	0.809	8	7	0.567	0.451
>12month	33	21	12			22	11
Camrelizumab combined modality								2.009	0.156
Chemoradiotherapy	25	21	4	10.290	0.001*	18	7
Others	23	9	14			12	11
Number of cycles of immune-therapy used				2.009	0.156			3.527	0.060*
<6 cycles	21	18	7			10	11
≥6 cycles	27	12	11			20	7